Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Hodgkin lymphoma, drawn from the whole corpus: 89 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Late toxicity in survivors.
Also on OnCo: Side effects by symptom · Immune-related side effects · Toxicity compare · Survivorship planner.
Older patients.
Late effects dominate: cardiac disease, breast and lung cancer after mediastinal radiotherapy, infertility; survivors need lifelong surveillance that most health systems do not organise.
Also on OnCo: Side effects by symptom · Immune-related side effects · Toxicity compare · Survivorship planner.
Older patients (>60) have roughly half the cure rate and double the toxicity; the best regimen for them is unsettled.
Also on OnCo: Side effects by symptom · Immune-related side effects · Toxicity compare · Survivorship planner.
The ~10-15% with primary refractory or early-relapsing disease still need transplant; those failing PD-1 blockade have few options beyond allogeneic transplant.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Resistance atlas · Lines of therapy.
Interim PET has limited positive predictive value; ctDNA-guided designs are unproven.
Access: brentuximab and nivolumab are costly and unavailable in many countries where EBV-positive Hodgkin lymphoma is common in children.
Nothing recorded yet.
Also on OnCo: Financial help · Coverage by country · HTA decisions.
Nodular lymphocyte-predominant disease is now a separate entity with little trial evidence of its own.
Radiotherapy omission trades a few percent of PFS for lower late toxicity; the right trade-off differs by age and sex.
Also on OnCo: Side effects by symptom · Immune-related side effects · Toxicity compare · Survivorship planner.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 51 changes by month →When this page itself was last checked or edited.
First-line advanced classical Hodgkin lymphoma with AVD, age ≥12 (SWOG S1826)
Untreated advanced classical Hodgkin lymphoma with AVD, age ≥12
Nivolumab-AVD × 6 (S1826; approved March 2026, no routine radiotherapy) or BV-AVD × 6 with G-CSF (ECHELON-1); in Europe PET-guided BrECADD × 4-6 (HD21) or eBEACOPP; PET-adapted ABVD/AVD (RATHL) where novel agents unavailable. (NCCN Category 1 (nivolumab-AVD preferred; BV-AVD), ESMO-MCBS A (ECHELON-1))
ABVD × 4 + ISRT 30 Gy, or escalated BEACOPP × 2 + ABVD × 2 + RT (HD14/HD17 PET-guided); nivolumab- or BV-containing regimens in trials. (NCCN Category 2A)
Salvage (ICE, DHAP, GVD, BV-nivolumab or pembrolizumab-GVD) → PET-negative → high-dose therapy and autologous transplant; brentuximab consolidation for high-risk (AETHERA); PD-1 maintenance in trials. (NCCN Category 1 (ASCT after chemosensitive salvage; BV consolidation for high risk))